Accelerating V940: A Strategic Blueprint for Translational to Late-Stage Clinical Development of Personalized Cancer Vaccines

• Integrating tumor profiling, neoantigen prediction, and manufacturing timelines to enable rapid patient-specific vaccine deployment

• Designing robust clinical trials to inform pivotal strategy: from patient selection to combination approaches

Speakers:

Michelle Brown

Vice President, Portfolio Development, Oncology

Moderna